ArticleCureus2025
Improvement in Glycemic Metrics With the First and Second Continuous Glucose Monitoring (CGM) Sensor Use in Indian Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing Continuous Glucose Monitoring Adoption in India: From Current Challenges to Future Solutions.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous glucose monitoring (CGM) provides the real-time monitoring of glycemic fluctuations. Better control of hemoglobin A1C (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) using Abbott FreeStyle Libre (Chicago, Illinois, United States) was reported. This study evaluated the glycemic outcomes in T2DM patients using Abbott FreeStyle Libre in Indian settings.
methodsIn this single-center retrospective study, data was collected from T2DM patients aged ≥18 years prescribed with Abbott FreeStyle Libre at Gupta Ultrasound and Heart Care Centre, New Delhi, India. The first application was considered the first use of FreeStyle Libre. The measurements were obtained from a sensor that operated continuously for as long as 14 days. The second application meant patients were using FreeStyle Libre for the second time continuously for 14 days following a break of two weeks after the first application. Time-in-range (TIR) is the percentage of time that a person spends with their blood glucose levels in a recommended target range. Time-below-range (TBR) is the time spent with blood sugar lower than the recommended range. Time-above-range (TAR) is the time spent above the recommended range. Relationship between TIR and various demographics/CGM metrics were analyzed.
resultsOverall, 649 and 60 patients were included from the first application and the second application, respectively. The average duration of DM was 10-15 years in most patients, with hypertension being the predominant comorbidity. TIR negatively correlated with lower HbA1c (r=-0.547; p<0.001), lower average glucose (r=-0.790; p<0.001), and TAR (r=-0.951; p<0.001) and positively correlated with TBR (r=0.190; p<0.001). TAR, TBR, and HbA1c were identified as significant predictors of TIR.
conclusionTIR from FreeStyle Libre showed a meaningful association with glycemic control, which could aid in optimizing treatment plans and improving clinical outcomes of T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.